Nilesh Sojitra, based at Spire Harpenden Hospital, spoke yesterday (Thursday 25th April 2013) to BBC three counties radio about the recent recommendations for the regulation of the cosmetic surgery industry. Both Mr Sojitra and Spire Harpenden Hospital welcome the reported findings of The NHS Medical Director, Professor Sir Bruce Keogh’s review into the UK’s cosmetic surgery industry.
The review has assessed the current rules in England, investigating products, practitioners, insurance, patient information and consent, advertising and marketing of cosmetic interventions.
Believed to be worth £2.3 billion in 2010 and estimated to rise to £3.6 billion by 2015 , the sector is growing at an incredible rate as people become increasingly accepting of the use of surgical and non-surgical procedures. Thousands of patients are treated each year and to date the non-surgical industry has been almost entirely unregulated.
Spire Healthcare is the second largest private hospital group in the UK and has witnessed a 10% increase in cosmetic surgery patients from 2011 to 2012.
Spire Healthcare’s Group Medical Director, Dr JJ de Gorter says, “A review of the cosmetic surgery industry is long overdue. I especially welcome the recommendation to establish a national implant register, as well as ensuring all those providing cosmetic interventions are properly registered to do so.”
Dr de Gorter also says that “All cosmetic surgeons working at Spire are on the GMC specialist register and hold appropriate indemnity cover. We are pleased the Keogh Review has put a spotlight on the cosmetic surgery industry and I believe these recommendations will prioritise patient safety and ensure individuals are able to access the best possible treatments with confidence.”
In addition to his interview Nilesh Sojitra stated: "It is fantastic that the Keogh report has made recommendations for which BAAPS have been campaigning for many years. Collection of data of cosmetic surgery interventions is vital to patient safety and for future improvement of practices. Dermal fillers requiring a prescription in the same way as Botox will help regulate the use and administration of them.
The report calls for patients to have consultations with the operating surgeon rather than patient advisors whose sole purpose is to generate sales and financial gain. The proposal to curtail prohibition of financial incentives for cosmetic interventions and therefore a tightening of the advertising code is welcomed and this will help protect vulnerable groups of patients. Practioners who use the term surgeon must be on the GMC Specialist Register and also work within the defined scope of practice for their designated specialty."
Spire Healthcare is the second largest private hospital provider in the UK, with 38 hospitals and ten clinics nationwide. The company is built on a heritage of almost 30 years’ experience running successful private hospitals and offers a full range of integrated surgical, medical and diagnostic services.
The company was formed from the sale of BUPA Hospitals to private equity company Cinven in 2007, followed by the purchase of Classic Hospitals and Thames Valley Hospital in 2008. Spire has since built Spire Shawfair Park Hospital (Edinburgh), Montefiore Hospital, acquired London Fertility Centre, and Lifescan. Since Spire was formed, performance improvements have included:
• Multiple Independent Healthcare Awards: ‘Medical Practice’ (2012) ‘Innovation’ (2011), ‘Risk Management’ and ‘Nursing Practice’ (2010 and 2009), ‘Healthcare Outcomes’ (2008) ‘Infection Control Excellence’ (2007)
• Increase in percentage of patients rating Spire ‘excellent’ or ‘very good’ - from 87% in 2008 to 92% in 2012*
• Increase in percentage of consultant surgeons rating Spire ‘excellent’ or ‘very good’ - from 51% in 2008 to 78% in 2012*
• Increase in percentage of employees who think Spire is a ‘great place to work’ - from 62% in 2009 to 78% in 2012
• EBITDAR uplifts from £127.4m in 2008 to £188.2m in 2011
For further information please visit: www.spirehealthcare.com.
* Rating options include ‘excellent’, ‘very good’, ‘quite good’, ‘quite poor’, ‘very poor’ and ‘totally unacceptable’
Department of Health, Review of the Regulation of Cosmetic Interventions, P5